Evommune (EVMN) director receives grant of 15,673 long-dated stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036. Following this grant, he holds options on 15,673 shares directly.
The award vests at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as Kirsch continues to serve through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KIRSCH ARTHUR S
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 15,673 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 15,673 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 15,673 shares
Exercise price: $19.82 per share
Expiration date: June 1, 2036
+1 more
4 metrics
Option grant size
15,673 shares
Stock Option (Right to buy) award to director
Exercise price
$19.82 per share
Conversion or exercise price of options
Expiration date
June 1, 2036
Option term end date
Post-grant derivative holdings
15,673 options
Total derivative shares following transaction
Key Terms
Stock Option (Right to buy), exercise price, expiration date, transaction code A, +1 more
5 terms
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
exercise price financial
"conversion_or_exercise_price: 19.8200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-01T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
transaction code A regulatory
"transaction_code: A (Grant, award, or other acquisition)"
underlying security financial
"underlying_security_title: Common Stock"
FAQ
What did Evommune (EVMN) director Arthur S. Kirsch report on this Form 4?
Arthur S. Kirsch reported receiving a stock option grant for 15,673 shares of Evommune common stock. The options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.
What are the terms of Arthur S. Kirsch’s new Evommune (EVMN) stock options?
Kirsch’s options cover 15,673 underlying shares at an exercise price of $19.82 per share. They expire on June 1, 2036, providing a long-dated right to purchase Evommune common stock if the vesting conditions are satisfied.
How and when do Arthur S. Kirsch’s Evommune (EVMN) option awards vest?
The options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual stockholder meeting. Vesting requires Kirsch to maintain continuous service with the company through the applicable vesting date, according to the reported footnote.
How many Evommune (EVMN) options does Arthur S. Kirsch hold after this filing?
After the reported grant, Kirsch holds stock options on 15,673 shares of Evommune common stock directly. The filing does not list any additional derivative positions in the derivative summary, so only this new award is shown as outstanding.